Molecule
Sevelamer is a phosphate binder indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease (CKD) on dialysis. MedsAcross supplies Sevelamer for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Renvela ® (sevelamer carbonate) is indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease (CKD) on dialysis. Renvela ® is a phosphate binder indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis.
Source: US FDA prescribing information
Renvela contains sevelamer carbonate, a non-absorbed phosphate-binding cross-linked polymer, free of metal and calcium. It contains multiple amines separated by one carbon from the polymer backbone. These amines exist in a protonated form in the intestine and interact with phosphate molecules through ionic and hydrogen bonding. By binding phosphate in the gastrointestinal tract and decreasing absorption, sevelamer carbonate lowers the phosphate concentration in the serum (serum phosphorus).
Source: US FDA prescribing information
Starting dose of Renvela is 0.8 or 1.6 grams administered orally three times per day with meals based on serum phosphorus levels for adult patients and based on body surface area (BSA) category for pediatric patients. Titrate by 0.8 g per meal in two-week intervals for adult patients as needed to obtain serum phosphorus target. Titrate based on BSA category for pediatric patients in two-week intervals for 6 weeks and then every 4 weeks as needed to obtain serum phosphorus target.
Source: US FDA prescribing information
Renvela is contraindicated in patients with bowel obstruction. Renvela is contraindicated in patients with known hypersensitivity to sevelamer carbonate, sevelamer hydrochloride, or to any of the excipients. Bowel obstruction. Known hypersensitivity to sevelamer carbonate, sevelamer hydrochloride, or to any of the excipients.
Source: US FDA prescribing information
Serious cases of dysphagia, bowel obstruction, bleeding gastrointestinal ulcers, colitis, ulceration, necrosis, and perforation have been associated with sevelamer use, some requiring hospitalization and surgery.
Source: US FDA prescribing information
Most of the safety experience is with sevelamer carbonate tablets and sevelamer hydrochloride. In long-term studies with sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, the most common adverse events included: vomiting (22%), nausea (20%), diarrhea (19%), dyspepsia (16%), abdominal pain (9%), flatulence (8%), and constipation (8%).
Source: US FDA prescribing information
There are no empirical data on avoiding drug interactions between Renvela and most concomitant oral drugs. For oral medication where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy (e.g., cyclosporine, tacrolimus, levothyroxine), consider separation of the timing of the administration of the two drugs. The duration of separation depends upon the absorption characteristics of the medication concomitantly administered, such as the time to reach peak systemic levels and whether the drug is an immediate-release or an extended-release product. Where possible consider monitoring clinical responses and/or blood levels of concomitant drugs that have a narrow therapeutic range.
Source: US FDA prescribing information
Store at 25°C (77°F): excursions permitted to 15°C–30°C (59°F–86°F). Protect from moisture.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
9 presentations of Sevelamer, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Sevelamer 800 mg tabletOralGeneric name | — | US FDA | Available on request |
| Sevelamer 800 mg powder for oral suspensionOralGeneric name | — | US FDA | Available on request |
| Sevelamer 2400 mg powder for oral suspensionOralGeneric name | — | US FDA | Available on request |
| Sevelamer 400 mg tabletOralGeneric name | — | US FDA | Available on request |
| Sevelamer 800 mg tabletParenteralGeneric name | — | US FDA | Available on request |
| Sevelamer 2400 mg/2790 mg powder for oral suspensionOralGeneric name | — | US FDA | Available on request |
| Renvela 2400 mg powder for oral suspensionOral | Genzyme | US FDA | Available on request |
| Renvela 800 mg tabletOral | Genzyme | US FDA | Available on request |
| Renvela 800 mg powder for oral suspensionOral | Genzyme | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Sevelamer in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 9 presentations of Sevelamer and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Sevelamer, including Renvela.
Yes. The US FDA first approved Sevelamer on 30 October 1998, according to Drugs@FDA.
Yes. Sevelamer has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Sevelamer is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Sevelamer is classified under ATC code V03AE02 (Sevelamer).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.